CT52923 是一种选择性的血小板衍生生长因子受体 (PDGFR) 拮抗剂，具有口服活性。CT52923 也是一种 ATP 竞争性抑制剂。CT52923 可用于病理疾病的研究，包括动脉粥样硬化、肾小球肾炎、肝硬化、肺纤维化和癌症。

CT52923 is a selective, orally active platelet-derived growth factor receptor (PDGFR) antagonist. CT52923 also is an ATP-competitive inhibitor. CT52923 can be used for the research variety of pathological diseases, including atherosclerosis, glomerulonephritis, liver cirrhosis, pulmonary fibrosis, and cancer.

CT52923 inhibits PDGFRs and stem cell factor receptors with IC50 values of 100 to 200 nM. CT52923（0.01-30 μ M； 24 h) blocks smooth muscle cell migration or fibroblast proliferation induced by platelet-derived growth factor, IC50 is 64 and 280 nM respectively [1].

CT52923 (oral; 5,15,30 and 50 mg/kg; twice daily) significantly inhibits the formation of neointima after carotid artery injury in rats [1].

205256-55-9

C23H25N5O4S

467.54

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years